Company Description
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States.
It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.
It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management.
The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Jonathan Javitt |
Contact Details
Address: 1201 N. Market Street, Suite 111 Wilmington, Delaware 19801 United States | |
| Phone | 484 254 6134 |
| Website | nrxpharma.com |
Stock Details
| Ticker Symbol | NRXP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1719406 |
| CUSIP Number | 629444209 |
| ISIN Number | US6294442099 |
| Employer ID | 82-2844431 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chairman, Chief Executive Officer and Chief Scientist Officer |
| Michael S. Abrams M.B.A. | Chief Financial Officer and Treasurer |
| Joseph M. Casper | Chief Operating Officer |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing and Technology Officer |
| Suzanne Messere | Investor Relations |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer and Director |
| Prof. Joshua C. Brown M.D., Ph.D. | Chief Medical Innovation Officer |
| Glenn Tyson | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 23, 2026 | ARS | Filing |
| Feb 23, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 424B5 | Filing |
| Feb 13, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 2, 2026 | 8-K | Current Report |